To install StudyMoose App tap and then “Add to Home Screen”
Save to my list
Remove from my list
The humanised antibody therapy compound under investigation is Durvalumab (MED14736), a monoclonal antibody designed to inhibit PD-L1 function, thereby stimulating the immune system to target and destroy cancerous cells. PD-L1 negatively regulates immune function in cancer and inflammatory diseases by interacting with the PD-1 receptor on T-Cells. Preventing the binding of PD-L1 to T-Cells is essential to maintain their function (OncoLink Team, 2019).
Durvalumab, also known commercially as Imfinzi, is a Human IgG1k monoclonal antibody approved for the treatment of various cancers, including Urothelial Carcinoma and Non-Small-Cell Lung Carcinoma (NSCLC).
It is produced by MedImmune, AstraZeneca, and Celgene.
According to Pfizer (2019), only a small fraction of molecules undergoing testing become therapeutic drugs, highlighting the rigorous pre-clinical and clinical trials required to ensure safety and efficacy. Experimental pharmacology aims to assess the effects, efficacy, and toxicity of pharmacological agents in various species.
In Silico, or computer-based experimentation, serves as the initial step in evaluating a new compound.
Verified writer
Proficient in: Biology
4.9 (247)
“ Rhizman is absolutely amazing at what he does . I highly recommend him if you need an assignment done ”
It involves the use of computational models and data integration to analyze biological and medical data globally (Ekins, Mestres, & Testa, 2007). In Silico methods facilitate the creation of models, simulations, predictions, and hypotheses, streamlining drug discovery.
In Vitro testing, conducted in controlled environments using isolated live cells, assesses the efficacy of a compound (Franks, T., 2018).
While it is time and cost-effective and provides relevant results using human cells, it lacks information on side effects and toxicity.
In Vivo testing, conducted in live animals, determines drug safety and toxicity before human trials (Franks, T., 2018). While reliable and specific, it is costly and time-consuming and must comply with strict ethical standards.
Based on the European Medicines Agency (Imfinzi Assessment Report), the following In Vitro tests are suitable for Durvalumab:
Suitable In Vivo tests for Durvalumab, based on the Imfinzi Assessment Report, include:
Toxicity testing is an integral part of In Vivo testing to assess adverse effects on living organisms. Key toxicity tests include:
Clinical trials for Durvalumab and similar drugs typically consist of three phases:
Once sufficient data is collected and the drug is deemed safe, it can proceed to market release.
The results of pre-clinical testing are crucial in determining the safety and efficacy of Durvalumab. In Silico testing provided valuable insights into the compound's potential, helping identify promising areas for further research.
In Vitro testing confirmed Durvalumab's binding affinity to PD-L1 and its ability to inhibit PD-L1 and PD-1 interaction, making it a potential candidate for immunotherapy.
In Vivo testing using murine models demonstrated the compound's anti-tumor activity in various cancer types, further supporting its potential as a therapeutic agent.
Toxicity testing is ongoing, and results will provide critical information about potential adverse effects on living organisms.
The pre-clinical testing of Durvalumab has shown promising results in terms of its efficacy in inhibiting tumor growth and its potential as an immunotherapy agent. Further research and clinical trials are needed to confirm its safety and effectiveness in humans. If successful, Durvalumab could offer new hope in the treatment of various cancers.
1. OncoLink Team. (2019). The PD-1/PD-L1 Pathway in Cancer. OncoLink. https://www.oncolink.org/cancer-treatment/immune-therapy/the-pd-1-pd-l1-pathway-in-cancer
2. Ekins, S., Mestres, J., & Testa, B. (2007). In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology, 152(1), 9-20.
3. Franks, T. (2018). In vitro models for drug discovery. Methods in Molecular Biology (Clifton, N.J.), 1683, 11-31.
4. Pfizer. (2019). The Journey of a Medicine: From Testing to Access. Pfizer. https://www.pfizer.com/research/rd-pipeline
Food Science and Environmental Health Laboratory Report. (2024, Jan 06). Retrieved from https://studymoose.com/document/food-science-and-environmental-health-laboratory-report
👋 Hi! I’m your smart assistant Amy!
Don’t know where to start? Type your requirements and I’ll connect you to an academic expert within 3 minutes.
get help with your assignment
